Eli Lilly Adds Amylin Receptor Agonists to Camurus Collaboration Agreement
Camurus announced on June 1, 2026 that Eli Lilly exercised its option to include amylin receptor agonists in their June 2025 collaboration and license agreement. The move triggers a $5 million payment and extends Lilly's rights to Camurus' FluidCrystal technology.
cnbc.comEli Lilly and Company exercised its option to include amylin receptor agonists in a collaboration and license agreement with Camurus, the Swedish company announced on June 1, 2026. The agreement, originally entered in June 2025, now covers up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP receptor agonists, triple agonists for GLP-1, GIP and glucagon receptors, and amylin receptor agonists.
The option exercise extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology to amylin receptor agonists.
The decision triggers a $5 million initial payment to Camurus. Under the agreement, Camurus is eligible to receive up to $290 million in upfront development and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single digit royalties on product sales.
The amylin receptor agonists are subject to the same milestone payments and royalty levels as the other compounds.
"Lilly's decision to exercise the option validates our technology, broadens our partnership and extends FluidCrystal into the expanding field of amylin therapeutics," said Fredrik Tiberg, President and CEO of Camurus. " Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods from days to months with a single injection.
The technology uses a prefilled syringe or autoinjector pen that transforms into a liquid crystalline gel upon contact with bodily fluids.
The liquid crystalline matrix gradually degrades in tissue to slowly release the drug. , and Australia. Camurus is an international science-led biopharmaceutical company headquartered in Lund, Sweden.
The company is committed to developing and commercializing innovative long-acting medicines using its proprietary FluidCrystal technology. Its R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. , and Australia.
The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. Fredrik Joabsson is Chief Business Development Officer of Camurus.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
Wildfire Insured Losses Hit $54 Billion in 2025, Highest on Record
A new analysis published Sunday found that insured losses from wildfires worldwide hit at least $54 billion in 2025, the highest level on record. The Los Angeles fires and blazes in South Korea and Spain drove the total.
Usa TodayGlobal Wildfire Area Burned in 2025 Second-Lowest Since 2002
A May 31 study found that 2025 produced the second-lowest global burned area since 2002, yet recorded the highest insured wildfire losses on record and more than 90 deaths.